Phase II Study of Pazopanib Maintenance for SCLC
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 18 Oct 2017 Primary endpoint (Progression-free survival) has been met, according to the results presented at the 18th World Conference on Lung Cancer.
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer
- 31 May 2017 Status changed from recruiting to active, no longer recruiting.